About this document

HPK1 As A Novel IO Drug Target, Elife, 2020 by 권준철 is a document available to read on EtoBox.

This review article discusses Hematopoietic Progenitor Kinase 1 (HPK1) as a potential target for immuno-oncology drug development, focusing on its role in negatively regulating T cell responses during the cancer-immunity cycle. The authors highlight the need for novel small molecule kinase inhibitors that can enhance the immune response against cancer, as current therapies show variable efficacy across different tumor types. The article also outlines the mechanisms of HPK1 activation and its implications fo

Author

권준철

Language

EN